AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 21 min read$PTGX

Ali Asif sold $8.3M of PTGX

Ali Asif (Chief Financial Officer) sold 58,629 shares of Protagonist Therapeutics, Inc (PTGX) at an average of $141.78 ($141.77–$141.78, $8.31M total) across 2 trades on 2026-09-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ali Asif
Published Oct 2, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 8:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PTGX
Bearish
medium confidence
Mentioned
$PTGX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PTGXBearishLow
01

Why it matters

The disclosed sale reduces insider ownership and may be interpreted as a lack of confidence, potentially prompting short‑term selling pressure.

02

Market read

Insider sale of $8.3M by the CFO is a material event for PTGX and could influence short‑term price action.

03

What to watch

The CFO may be diversifying personal holdings; the 10b5‑1 plan pre‑arranged, not necessarily a negative signal.

Relevance 5/10Novelty 6/10Timing: today

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the CFO's sale.

Company-level read

Ticker impact

$PTGXBearishMedium confidence
Context

CFO Ali Asif sold 58,629 shares for $8.3M via a 10b5‑1 plan, reducing his stake to 59,003 shares.

Expected impact

likely downward pressure as investors price in the insider sale

Evidence & confidence

A CFO sale of over $8M is material for a mid‑cap biotech and is disclosed for the first time.

Market effects

Sector

May raise concerns for other biotech stocks if investors view insider sales as a red flag.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Minimal global impact; primarily relevant to PTGX shareholders.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • person
    Ali Asif

    Chief Financial Officer of Protagonist Therapeutics

  • company
    Protagonist Therapeutics, Inc.

    Biotech firm developing therapies for rare diseases

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PTGX insider trading history →

Related articles

SEP 8
$PTGXHighAI 8/10

Protagonist Therapeutics Announces $300 Million Share Repurchase Program

Protagonist Therapeutics (PTGX) announced a $300M share repurchase program, funded by cash reserves and collaboration payments. The program may be executed through open market purchases or other transactions, with timing and amounts dependent on market conditions and other factors. As of June 30, 2026, the company had $849.5M in cash, cash equivalents, and marketable securities, excluding recent milestone payments.

finanznachrichten.de2 min
SEP 6
$PTGXMedAI 8/10

Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status

Protagonist Therapeutics (PTGX) reported a $162.8M profit in Q2 2026, reversing a $34.8M loss from the prior year. The turnaround was driven by milestone payments for two drugs, ICOTYDE and rusfertide, with cash reserves reaching $849.5M. ICOTYDE, approved for psoriasis, triggered a $50M payment and potential $580M more from J&J. Rusfertide, awaiting FDA decision, has already brought in $200M from Takeda, with more milestones pending.

yahoo.com3 min
SEP 4
$PTGXMedAI 8/10

MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?

FDA approval of MIMRYLO triggered $275M in payments to Protagonist Therapeutics (PTGX), including a $200M opt-out fee and a $75M milestone. PTGX chose royalties over a 50:50 profit split with Takeda (TAK), opting for non-dilutive capital and lower execution risk. PTGX is eligible for up to $875M in additional milestones. The royalty structure ranges from 14% to 29% on worldwide net sales.

insidermonkey.com3 min
SEP 1
$PTGXHighAI 9/10

FDA approves Protagonist and Takeda’s drug for rare blood cancer

FDA approved Protagonist Therapeutics' and Takeda's drug rusfertide (Mimrylo) for polycythemia vera. Mimrylo, a weekly injection, controls red blood cell overproduction. Takeda has not disclosed the price. Analysts forecast peak sales up to $2B. Protagonist's stock has nearly tripled in a year. Mimrylo is Takeda's second of three anticipated drug launches.

bostonglobe.com2 min